Trial Information
Inclusion Criteria:
- Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of
imatinib therapy.
Exclusion Criteria:
- Patients in imatinib study
- Patients with a history of intolerability to interferon.
- Patients with less than CCR or less than one year of imatinib therapy.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Izhar Hardan, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Sheba Medical Center
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
SHEBA-06-4015-IH-CTIL
NCT ID:
NCT00297570
Start Date:
February 2006
Completion Date:
Related Keywords:
- Leukemia, Myeloid, Philadelphia-Positive
- CML
- Imatinib
- Pegylated Interferon
- Philadelphia Positive CML
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive